LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Meghan FitzGerald has been appointed to its Board of Directors and will serve as a member of its compensation committee effective March 22, 2016.
“We are delighted to welcome Meg to our Board of Directors,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “She is an accomplished executive with broad expertise in the healthcare industry who will provide important breadth to our Board as we advance and broaden our pipeline of innovative therapeutics.”
